SNY logo

SANOFI-ADR

SNYNASDAQ
๐Ÿ† #141 by market capEarnings Oct 30 ยท PreUS Equity
$42.24โ–ฒ $0.35 (+0.84%)
๐ŸŒ™ After hours$42.02โ–ผ 0.52%Regular close ยท extended-hours price shown
๐Ÿ””
Track SNY
Get earnings, price moves & breaking news on Telegram
Track
24hโ–ฒ 0.8%
7dโ€”
14dโ€”
30dโ€”
ytdโ€”
1yโ€”
๐ŸฆMarket Cap
$51.02B
Mid Cap
๐Ÿ“ˆRevenue Growth (YoY)
13.4%
Healthy
๐Ÿ“ŠGross Margin
72.8%
High
๐Ÿ’ตFCF Margin
14.5%
Healthy
โš–๏ธP/S Ratio
1.8x
Cheap
Otter Score
84
Strong
No chart data available for SNY.

Trading Snapshot

Day Range
$41.63 โ€“ $42.28
52-Week Range
โ€”
Volume (shares)
2,909,387
Avg Volume (shares)
โ€”
Shares Outstanding
1.21B
Next Earnings
2026-10-30

Fundamentals Snapshot

Annual Revenue
$46.72B
Last Q Revenue
$12.30B
P/E Ratio
22.5
P/S Ratio
1.8x
EPS (TTM)
โ€”
Dividend Yield
10.90%
Dilution (1yr)
โˆ’2.6%
SNY logo

SANOFI-ADR

SNY
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$46.7Bโ–ฒ +5.5% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
72.1%โ–ฒ +2.7% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isnโ€™t profitable yet.
$9.6Bโ–ฒ +32.3% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$10.1Bโ–ฒ +72.3% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing ownerโ€™s slice.
2.44Bโ–ผ โˆ’2.6% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
โˆ’$12.7Bโ–ผ โˆ’$2.2B YoY
StockOtter ยท stockotter.space

About SANOFI-ADR

Sanofi operates as a leading global pharmaceutical enterprise, dedicated to the research, development, production, and distribution of a wide array of therapeutic solutions across the United States, Europe, and numerous international markets. The company strategically organizes its operations into three core divisions: Pharmaceuticals, Vaccines, and Consumer Healthcare. Within its Pharmaceutical segment, Sanofi delivers specialized therapies, including innovative human monoclonal antibodies, addressing complex conditions like multiple sclerosis, various neurological disorders, immunology and inflammatory diseases, oncology, rare diseases, and rare blood disorders. This segment also encompasses treatments for diabetes, cardiovascular health, and established prescription medications. Its Vaccine portfolio is extensive, offering essential immunizations such as pediatric vaccines for poliomyelitis, pertussis, and Hib, alongside influenza shots, adult boosters, meningitis vaccines, and solutions for travel and endemic diseases. The Consumer Healthcare division provides a broad spectrum of over-the-counter products, including remedies for allergies, coughs and colds, pain management, liver support, physical and mental wellness, probiotics, digestive health aids, and nutritional supplements. Additionally, it offers various personal care items like daily body lotions, anti-itch creams, moisturizing and soothing lotions, body and foot creams, and specialized powders for eczema. Sanofi maintains a robust development pipeline, with numerous pharmaceutical products and vaccines currently in various stages of research. The company actively pursues strategic alliances, exemplified by its collaboration with GlaxoSmithKline on a recombinant Covid-19 vaccine, a research partnership with Stanford University School of Medicine focused on advancing immunology and inflammation understanding, and a collaboration and license option agreement with Prellis Biologics, Inc. Founded in 1973 and headquartered in Paris, France, the company was formerly known as Sanofi-Aventis before officially changing its name to Sanofi in May 2011.

๐Ÿฆฆ

Otter Score Breakdown

How it's scoredFive components, each rated 1โ€“5โ˜… and equally weighted (20%), averaged to a 0โ€“100 score:๐Ÿ’Ž Quality โ€” gross margin๐Ÿš€ Growth โ€” revenue YoYโš–๏ธ Valuation โ€” P/S ratioโšก Momentum โ€” 30-day price change๐Ÿ’ง Dilution โ€” 1-yr share issuance (buybacks score higher)
๐Ÿ’ŽQualityโ˜…โ˜…โ˜…โ˜…โ˜…
๐Ÿš€Growthโ˜…โ˜…โ˜…โ˜…โ˜…
โš–๏ธValuationโ˜…โ˜…โ˜…โ˜…โ˜…
โšกMomentumโ˜…โ˜…โ˜…โ˜…โ˜…
๐Ÿ’งDilutionโ˜…โ˜…โ˜…โ˜…โ˜…
Overall Score
Strong
84/100

Analyst Ratings

โ“˜
Consensus
Buy
31 analysts
Strong Buy7
Buy10
Hold13
Sell1
Strong Sell0
Ratings as of Oct 2026

Latest News & Updates

24/7 Wall Streetยท2d ago

Regeneron's Billion-Dollar Catalyst Flying Under Wall Street's Radar Ahead of Oct. 30 Earnings

Regeneron (NASDAQ:REGN | REGN Price Prediction) reports third-quarter results on Oct. 30. Regeneron books its full share of Dupixent profits from Sanofi (NASDAQ:SNY) for the first time this quarter.

Seeking Alphaยท2d ago

Sanofi: An Alluring And Balanced Mix Of Yield And Growth

Sanofi has increased its dividend for 31 consecutive years. It's only because this is not an American company in the S&P 500 that it's not a dividend aristocrat. Sanofi increased its revenue from โ‚ฌ34.7 billion in FY 2016

Seeking Alphaยท8d ago

Sanofi: Why The Market Seems To Be Overpricing Pipeline Risk

Sanofi is deeply undervalued, trading at 8.4x P/E despite AA rating, robust balance sheet, and a 5.8% dividend yield. I see SNY pipeline risks as overstated; Dupixent's expansion and multiple smaller launches provide sol

Business Wireยท8d ago

ScionxBio Announces Collaboration to Develop Long-Acting xRNA Therapeutics

CAMBRIDGE, England--(BUSINESS WIRE)--ScionxBio (the โ€œcompanyโ€, operating as a brand identity of Eleven Therapeutics Ltd. following a horizontal split) a privately held, preclinical-stage biotechnology company pioneering

GlobeNewsWireยท9d ago

Enable Injections Announces Approval in Japan for CirCLIQยฎ Injector based on enFuseยฎ On-Body Delivery System

Sanofi's CirCLIQยฎ Injector, developed using enFuse technology, has been approved to administer Sarclisa subcutaneous formulation, in combination with approved standard-of-care regimens, for patients with multiple myeloma

GlobeNewsWireยท9d ago

Press Release: Sanofi breaks ground on new state-of-the-art insulin manufacturing facility in Germany

Sanofi breaks ground on new state-of-the-art insulin manufacturing facility in Germany Paris and Frankfurt, October 19, 2 026. Sanofi today broke ground on a new state-of-the-art insulin manufacturing facility at its Bio